Altogether, these preclinical studies are encouraging towards the use of the MEK-ERK pathway inhibitors as safe and effective cardiovascular drugs targeting cardiac hypertrophy with aberrant ERK activation. Here, MAP2K7 is linked to cardiac hypertrophy.